trending Market Intelligence /marketintelligence/en/news-insights/trending/f7Bv83Awh-C7d0FAqXBjGg2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Braeburn Pharmaceuticals withdraws IPO


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Braeburn Pharmaceuticals withdraws IPO

Braeburn Pharmaceuticals Inc. withdrew plans for an IPO due to uncertainty in the U.S. healthcare industry, Reuters reported.

The Princeton, N.J.-based company was looking to offer 7.7 million shares in the $18 per share to $21 per share range but will consider such a move at a later date.

Apple Tree Partners, a private equity and venture capital firm, is the sole shareholder of Braeburn Pharmaceuticals, which manufactures implants for opioid addiction.